Luckily, for those who read the fine print, Canaccord discloses it receives fees from Vulcan as a manager of its capital raisings, while Alster has an “agreement on the production of the research report” with Vulcan, and has previously passed its draft reports to Vulcan before publishing.
While we can only guess the level of fees Canaccord receives for its research that has maintained a “speculative buy” rating on the stock, Alster confirmed that for just €17,500 a year ($27,400), companies can access “full coverage” which includes the analyst notes being hosted on its “research hub” platform. Coincidentally, Alster has consistently rated Vulcan as a “buy”. Canaccord had not provided a response at the time of going to press.
CROSS VUL out put LKE in exact same PAID PR BS reports with LKE 10 times worse imo
- Forums
- ASX - By Stock
- Bell Potter initiates coverage for LKE with A$1.37 SP target
Luckily, for those who read the fine print, Canaccord discloses...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LKE (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.2¢ |
Change
0.003(5.08%) |
Mkt cap ! $102.8M |
Open | High | Low | Value | Volume |
6.0¢ | 6.3¢ | 6.0¢ | $300.6K | 4.888M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 113043 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.3¢ | 537045 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 113043 | 0.062 |
6 | 737900 | 0.061 |
9 | 1408150 | 0.060 |
15 | 965763 | 0.059 |
11 | 1276308 | 0.058 |
Price($) | Vol. | No. |
---|---|---|
0.063 | 537045 | 10 |
0.064 | 916867 | 13 |
0.065 | 496823 | 10 |
0.066 | 383738 | 6 |
0.067 | 682000 | 5 |
Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
6.2¢ |
  |
Change
0.003 ( 3.16 %) |
|||
Open | High | Low | Volume | ||
6.0¢ | 6.3¢ | 6.0¢ | 2590872 | ||
Last updated 15.58pm 06/05/2024 ? |
Featured News
LKE (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online